Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Biodexa Pharmaceuticals ( (BDRX) ) is now available.
Biodexa Pharmaceuticals announced a change in the ratio of its American Depositary Receipts (ADRs), effective July 31, 2025, from one ADR representing 10,000 ordinary shares to one ADR representing 100,000 ordinary shares. This move, akin to a one-for-ten reverse ADR split, aims to meet Nasdaq’s $1.00 minimum bid price requirement, although there is no assurance of its success. The ordinary shares of the company remain unaffected by this change.
The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.
Spark’s Take on BDRX Stock
According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.
Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.
To see Spark’s full report on BDRX stock, click here.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on acquisitions and developing innovative products for treating diseases with unmet medical needs.
Average Trading Volume: 2,615,669
Technical Sentiment Signal: Sell
Current Market Cap: $584.3K
For detailed information about BDRX stock, go to TipRanks’ Stock Analysis page.